{
  "pmcid": "3144300",
  "sha256": "74ec4c7078eb811d1b2f1023877d699a09c1b9cca4e46e481270f80613afa4a5",
  "timestamp_utc": "2025-11-09T23:47:30.546828+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.851643700787402,
    "reading_ease": 16.85888287401579,
    "word_count": 254
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Adverse Event Reporting in Pediatric Heart Network Surgical Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomized to either a standard adverse event reporting system (period 1) or a system focusing on serious adverse event reporting for six sentinel events (period 2)."
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted in a multicenter setting, the trial included infants eligible for Norwood surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing systemic–pulmonary artery shunt versus right ventricle–pulmonary artery conduit"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate a novel adverse event reporting strategy in a randomized surgical trial"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the rate of serious adverse events from randomization to hospital discharge after stage II surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was performed using a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 infants were randomized, 100 to each group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "In period 2, the rate of serious adverse events requiring expedited reporting decreased significantly (0.42 vs 0.14/subject/month; P < .001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the control group, with 3% experiencing mild gastrointestinal side-effects compared to 1% in the intervention group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}